Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | GALR3 | O60755 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30356385 | 1.00 | ALDH1A1 (0.61) | ALDH1A1HPGDCYP1A2MAPTKMT2A | |
| SCHEMBL28545012 | 0.83 | ALDH1A1 (0.61) | ALDH1A1HPGDCYP1A2MAPTKMT2A | |
| SCHEMBL30249448 | 0.83 | ALDH1A1 (0.63) | ALDH1A1HPGDCYP1A2MAPTKMT2A | |
| SCHEMBL18214 | 0.83 | ALDH1A1 (0.63) | ALDH1A1HPGDCYP1A2MAPTKMT2A | |
| SCHEMBL30526110 | 0.83 | FLT1 (0.49) | ALDH1A1HPGDCYP1A2MAPTKMT2A | |
| SCHEMBL257466 | 0.83 | FLT1 (0.49) | ALDH1A1HPGDCYP1A2MAPTKMT2A | |
| SCHEMBL31173096 | 0.82 | HPGD (0.50) | ALDH1A1HPGDCYP1A2MAPTKMT2A | |
| SCHEMBL1330174 | 0.81 | ALDH1A1 (0.59) | ALDH1A1HPGDCYP1A2MAPTKMT2A | |
| SCHEMBL10462650 | 0.81 | ALDH1A1 (0.61) | ALDH1A1HPGDCYP1A2MAPTKMT2A | |
| SCHEMBL1396978 | 0.81 | ALDH1A1 (0.65) | ALDH1A1HPGDCYP1A2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 394 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120157566-A | Synthesis method and application of dapagliflozin intermediate | 江西华士药业有限公司 | 2025-06-17 | — | — | CN | claimed |
| CN-114288972-B | Reaction equipment for dapagliflozin intermediate and preparation method thereof | 浙江拓普药业股份有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-114369021-B | Preparation method and application of 2-chloro-5-bromobenzoyl chloride | 黑龙江立科新材料有限公司 | 2023-12-19 | — | — | CN | claimed |
| CN-116283513-A | Preparation method of dapagliflozin intermediate ortho-isomer impurity | 河南立诺制药有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-116041152-A | Preparation method of dapagliflozin brominated side chain isomer impurity | 河南立诺制药有限公司 | 2023-05-02 | — | — | CN | claimed |
| EP-4161912-A1 | PREPARATION OF HIGHLY PURE AMORPHOUS DAPAGLIFLOZIN | KRKA, d.d., Novo mesto (SI) | 2023-04-12 | — | — | EP | claimed |
| CN-115867538-A | Preparation of highly pure amorphous dapagliflozin | 新梅斯托克公司 | 2023-03-28 | — | — | CN | claimed |
| CN-115073271-A | Preparation method of 4' - (5-bromo-2-chlorobenzyl) phenol | 苏州敬业医药化工有限公司 | 2022-09-20 | — | — | CN | claimed |
| CN-114773373-A | Preparation method of engagliflozin key intermediate and engagliflozin impurity | 浙江普洛家园药业有限公司 | 2022-07-22 | — | — | CN | claimed |
| CN-114369021-A | Preparation method and application of 2-chloro-5-bromobenzoyl chloride | 黑龙江立科新材料有限公司 | 2022-04-19 | — | — | CN | claimed |
| CN-114288972-A | Reaction equipment for dapagliflozin intermediate and preparation method thereof | 浙江拓普药业股份有限公司 | 2022-04-08 | — | — | CN | claimed |
| CN-111662166-A | Preparation method of 5-bromo-2-chloro-4' -ethoxy diphenylmethane | 吴赣药业（苏州）有限公司 | 2020-09-15 | — | — | CN | claimed |
| CN-111099975-A | Preparation method of 5-bromo-2-chloro-4' -ethoxy benzophenone | 河北合佳医药科技集团股份有限公司 | 2020-05-05 | — | — | CN | claimed |
| US-10556877-B2 | Process for preparation of dapagliflozin | GLENMARK LIFE SCIENCES LIMITED (IN) | 2020-02-11 | — | — | US | claimed |
| CN-105061373-B | A kind of synthetic method of Dapagliflozin isomer impurities | 合肥华方医药科技有限公司 | 2017-10-20 | — | — | CN | claimed |
| CN-107200683-A | A kind of preparation method for being used to treat type II diabetes Dapagliflozin intermediate | 青岛辰达生物科技有限公司 | 2017-09-26 | — | — | CN | claimed |
| CN-104086379-B | The synthetic method of the clean intermediate of Da Gelie | ANHUI LIANCHUANG BIOLOGICAL MEDICINE CO., LTD. (CN) | 2015-08-12 | — | — | CN | claimed |
| CN-104341444-A | Empagliflozin silicon-containing aglycone as well as preparation method and application thereof | UNIV GUANGXI CHINESE MEDICINE | 2015-02-11 | — | — | CN | claimed |
| CN-103570510-A | One-pot synthesis method for 5-bromo-2-chloro-4'-ethoxy diphenylmethane | CHINATECH PEPTIDE CO LTD | 2014-02-12 | — | — | CN | claimed |
| CN-120157566-A | Synthesis method and application of dapagliflozin intermediate | 江西华士药业有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-120157566-A | Synthesis method and application of dapagliflozin intermediate | 江西华士药业有限公司 | 2025-06-17 | — | — | CN | disclosed |
| WO-2025088634-A1 | A PROCESS FOR THE PREPARATION OF GLIFLOZIN AGLYCONES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2025-05-01 | — | — | WO | disclosed |
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-12-19 | — | — | US | disclosed |
| CN-118851889-A | Preparation method of Liujing intermediate | 浙江永太科技股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-12116351-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-10-15 | — | — | US | disclosed |
| CN-118546055-A | Preparation method of (1R, 3S, 5S) -3- (4- (5-bromo-2-chlorobenzyl) phenoxy) bicyclo [3.1.0] hexane | 山东科巢生物制药有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-12071418-B2 | Processes for preparation of dapagliflozin or its solvates or co-crystals thereof | LAURUS LABS LIMITED (IN) | 2024-08-27 | — | — | US | disclosed |
| US-20240245633-A1 | ROR Gamma Agonists as Enhancers of Protective Immunity | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-07-25 | — | — | US | disclosed |
| CN-114288972-B | Reaction equipment for dapagliflozin intermediate and preparation method thereof | 浙江拓普药业股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-115894452-B | P2X7 receptor inhibitor | 四川大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-117720401-A | Synthesis method of dapagliflozin intermediate | 江苏阿尔法药业股份有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-115445242-B | Device and method for treating dapagliflozin intermediate mother liquor | 浙江工业大学 | 2024-03-01 | — | — | CN | disclosed |
| CN-114369021-B | Preparation method and application of 2-chloro-5-bromobenzoyl chloride | 黑龙江立科新材料有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-114369021-B | Preparation method and application of 2-chloro-5-bromobenzoyl chloride | 黑龙江立科新材料有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-114369021-B | Preparation method and application of 2-chloro-5-bromobenzoyl chloride | 黑龙江立科新材料有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-116354799-A | Preparation method of dapagliflozin intermediate | 江苏阿尔法药业股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-116283513-A | Preparation method of dapagliflozin intermediate ortho-isomer impurity | 河南立诺制药有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-115417836-B | Method for synthesizing Liujing hypoglycemic intermediate by using continuous flow | 安庆奇创药业有限公司 | 2023-05-19 | — | — | CN | disclosed |
| CN-116041152-A | Preparation method of dapagliflozin brominated side chain isomer impurity | 河南立诺制药有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-108285439-B | Carbonoside sodium glucose transport protein body 2 inhibitor | 江苏天士力帝益药业有限公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-4161912-A1 | PREPARATION OF HIGHLY PURE AMORPHOUS DAPAGLIFLOZIN | KRKA, d.d., Novo mesto (SI) | 2023-04-12 | — | — | EP | disclosed |
| CN-115867538-A | Preparation of highly pure amorphous dapagliflozin | 新梅斯托克公司 | 2023-03-28 | — | — | CN | disclosed |
| WO-2023005587-A1 | SYNTHESIS METHOD FOR EMPAGLIFLOZIN KEY INTERMEDIATE | 山东铂源药业股份有限公司 | 2023-02-02 | — | — | WO | disclosed |
| CN-110049975-B | Process for the preparation of 5- (1-phenyl-1H-pyrazol-4-yl) nicotinamide derivatives | 拜耳作物科学股份公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115445242-A | Treatment device and method for dapagliflozin intermediate mother liquor | 浙江工业大学 | 2022-12-09 | — | — | CN | disclosed |
| CN-115417836-A | Method for synthesizing lean hypoglycemic drug intermediate by using continuous flow | 安庆奇创药业有限公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20220380322-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-12-01 | — | — | US | disclosed |
| US-20220372010-A1 | PROCESSES FOR PREPARATION OF DAPAGLIFLOZIN OR ITS SOLVATES OR CO-CRYSTALS THEREOF | LAURUS LABS LIMITED (IN) | 2022-11-24 | — | — | US | disclosed |
| CN-110551088-B | Deuterium-modified benzyl-4-chlorophenyl C-glycoside derivatives | 北京惠之衡生物科技有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-115073271-A | Preparation method of 4' - (5-bromo-2-chlorobenzyl) phenol | 苏州敬业医药化工有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-11434207-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-09-06 | — | — | US | disclosed |
| US-11427555-B2 | Processes for preparation of dapagliflozin or its solvates or co-crystals thereof | LAURUS LABS LIMITED (IN) | 2022-08-30 | — | — | US | disclosed |
| EP-3497090-B1 | NOVEL PROCESSES FOR PREPARATION OF DAPAGLIFLOZIN OR ITS SOLVATES OR CO-CRYSTALS THEREOF | LAURUS LABS LTD (IN) | 2022-08-03 | — | — | EP | disclosed |
| CN-106892948-B | Glucopyranosyl derivative and application thereof in medicine | 宜昌东阳光长江药业股份有限公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-114773373-A | Preparation method of engagliflozin key intermediate and engagliflozin impurity | 浙江普洛家园药业有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-111995507-B | Application of combined catalyst in specific Friedel-crafts reaction | 浙江宏元药业股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| US-RE49080-E1 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2022-05-24 | — | — | US | disclosed |
| CN-114369021-A | Preparation method and application of 2-chloro-5-bromobenzoyl chloride | 黑龙江立科新材料有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-114369021-A | Preparation method and application of 2-chloro-5-bromobenzoyl chloride | 黑龙江立科新材料有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-114369021-A | Preparation method and application of 2-chloro-5-bromobenzoyl chloride | 黑龙江立科新材料有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-114315534-A | Preparation method of dapagliflozin intermediate | 山东鲁宁药业有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-114288972-A | Reaction equipment for dapagliflozin intermediate and preparation method thereof | 浙江拓普药业股份有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-110724123-B | Synthesis method of canagliflozin intermediate | 扬州工业职业技术学院 | 2022-03-01 | — | — | CN | disclosed |
| US-20210388016-A1 | GLUCOPYRANOSE DERIVATIVES USEFUL AS SGLT2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-16 | — | — | US | disclosed |
| US-20210388015-A1 | GLUCOPYRANOSE DERIVATIVES USEFUL AS SGLT2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-16 | — | — | US | disclosed |
| CN-109232199-B | Synthesis method of 1-chloro-2- (4-ethoxybenzyl) -4-iodobenzene | 南京红杉生物科技有限公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-108863959-B | P2X4 receptor antagonists | 日本化学药品株式会社 | 2021-11-30 | — | — | CN | disclosed |
| US-20210323939-A1 | NOVEL PROCESSES FOR PREPARATION OF DAPAGLIFLOZIN OR ITS SOLVATES OR CO-CRYSTALS THEREOF | LAURUS LABS LIMITED (IN) | 2021-10-21 | — | — | US | disclosed |
| CN-112920030-A | Method for preparing dapagliflozin intermediate by one-pot method | 安庆奇创药业有限公司 | 2021-06-08 | — | — | CN | disclosed |
| US-10981888-B2 | Preparation method for tricyclic compounds | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2021-04-20 | — | — | US | disclosed |
| EP-3251679-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-12-16 | — | — | EP | disclosed |
| CN-111995507-A | Application of combined catalyst in specific Friedel-crafts reaction | 浙江宏元药业股份有限公司 | 2020-11-27 | — | — | CN | disclosed |
| EP-2896397-B2 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-10-07 | — | — | EP | disclosed |
| CN-111662166-A | Preparation method of 5-bromo-2-chloro-4' -ethoxy diphenylmethane | 吴赣药业（苏州）有限公司 | 2020-09-15 | — | — | CN | disclosed |
| CN-111662166-A | Preparation method of 5-bromo-2-chloro-4' -ethoxy diphenylmethane | 吴赣药业（苏州）有限公司 | 2020-09-15 | — | — | CN | disclosed |
| EP-1651658-B2 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-08-12 | — | — | EP | disclosed |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2020-07-16 | — | — | US | disclosed |
| CN-108675976-B | 6-halogenated glucose carbon glycoside and preparation method and application thereof | 浙江宏元药业股份有限公司 | 2020-07-14 | — | — | CN | disclosed |
| CN-111333588-A | P2X4 receptor antagonists | 日本化学药品株式会社 | 2020-06-26 | — | — | CN | disclosed |
| CN-111099975-A | Preparation method of 5-bromo-2-chloro-4' -ethoxy benzophenone | 河北合佳医药科技集团股份有限公司 | 2020-05-05 | — | — | CN | disclosed |
| CN-111099975-A | Preparation method of 5-bromo-2-chloro-4' -ethoxy benzophenone | 河北合佳医药科技集团股份有限公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10633349-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2020-04-28 | — | — | US | disclosed |
| CN-104066724-B | P2X4 receptor antagonists | 日本化学药品株式会社 | 2020-04-17 | — | — | CN | disclosed |
| EP-2900657-B1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2020-03-11 | — | — | EP | disclosed |
| US-10556877-B2 | Process for preparation of dapagliflozin | GLENMARK LIFE SCIENCES LIMITED (IN) | 2020-02-11 | — | — | US | disclosed |
| CN-110724123-A | Synthesis method of canagliflozin intermediate | 扬州工业职业技术学院 | 2020-01-24 | — | — | CN | disclosed |
| CN-110551088-A | deuterium-modified benzyl-4-chlorophenyl C-glycoside derivatives | XUANZHU BEIJING MEDICINE TECH CO LTD | 2019-12-10 | — | — | CN | disclosed |
| US-20190315707-A1 | PREPARATION METHOD FOR TRICYCLIC COMPOUNDS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-10-17 | — | — | US | disclosed |
| EP-3551616-A1 | METHOD FOR PRODUCING 5-(1-PHENYL-1H-PYRAZOLE-4-YL)-NICOTINAMIDE DERIVATIVES AND SIMILAR COMPOUNDS WITHOUT ISOLATING OR PURIFYING THE PHENYLHYDRAZINE INTERMEDIATE | Bayer CropScience Aktiengesellschaft (DE) | 2019-10-16 | — | — | EP | disclosed |
| CN-110049975-A | Process for the preparation of 5- (1-phenyl-1H-pyrazol-4-yl) nicotinamide derivatives and analogous compounds without isolation or purification of phenylhydrazine intermediates | 拜耳作物科学股份公司 | 2019-07-23 | — | — | CN | disclosed |
| CN-106316803-B | A kind of synthetic method of SGLT-2 inhibitor intermediate | 重庆博腾制药科技股份有限公司 | 2019-07-09 | — | — | CN | disclosed |
| US-20190202814-A1 | PROCESSES FOR PREPARATION OF EMPAGLIFLOZIN | CADILA HEALTHCARE LIMITED (IN) | 2019-07-04 | — | — | US | disclosed |
| EP-3497090-A1 | NOVEL PROCESSES FOR PREPARATION OF DAPAGLIFLOZIN OR ITS SOLVATES OR CO-CRYSTALS THEREOF | Laurus Labs Limited (IN) | 2019-06-19 | — | — | EP | disclosed |
| CN-109867648-A | A kind of synthetic method of Yi Palie only in relation to substance IMPD | 浙江医药股份有限公司新昌制药厂 | 2019-06-11 | — | — | CN | disclosed |
| US-10253010-B2 | C-glycoside derivative | SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. (CN) | 2019-04-09 | — | — | US | disclosed |
| US-20180282363-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-10-04 | — | — | US | disclosed |
| US-20180201587-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2018-07-19 | — | — | US | disclosed |
| WO-2018104214-A1 | METHOD FOR PRODUCING 5-(1-PHENYL-1H-PYRAZOLE-4-YL)-NICOTINAMIDE DERIVATIVES AND SIMILAR COMPOUNDS WITHOUT ISOLATING OR PURIFYING THE PHENYLHYDRAZINE INTERMEDIATE | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-06-14 | — | — | WO | disclosed |
| US-9969700-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD. (JP) | 2018-05-15 | — | — | US | disclosed |
| US-20180127391-A1 | PROCESS FOR PREPARATION OF DAPAGLIFLOZIN | ALIVUS LIFE SCIENCES LIMITED (IN) | 2018-05-10 | — | — | US | disclosed |
| EP-2230907-B1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | THERACOS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-3318562-A2 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | Theracos Sub, LLC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-9931323-B2 | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9926276-B2 | Substituted benzamides with activity towards EP4 receptors | DRACONIS PHARMA, S.L. (ES) | 2018-03-27 | — | — | US | disclosed |
| US-9914688-B2 | Optically pure benzyl-4-chlorophenyl-C-glucoside derivative | SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. (CN) | 2018-03-13 | — | — | US | disclosed |
| US-9914688-B2 | Optically pure benzyl-4-chlorophenyl-C-glucoside derivative | SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. (CN) | 2018-03-13 | — | — | US | disclosed |
| US-9895389-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-9895389-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| WO-2018029611-A1 | NOVEL PROCESSES FOR PREPARATION OF DAPAGLIFLOZIN OR ITS SOLVATES OR CO-CRYSTALS THEREOF | LAURUS LABS LIMITED (IN) | 2018-02-15 | — | — | WO | disclosed |
| CN-107652278-A | A kind of synthesis technique net Yi Palie | 江苏工程职业技术学院 | 2018-02-02 | — | — | CN | disclosed |
| CN-107652277-A | A kind of preparation method net Yi Palie | 江苏工程职业技术学院 | 2018-02-02 | — | — | CN | disclosed |
| CN-107652276-A | A kind of preparation method net SGLT2 inhibitor Yi Palie | 江苏工程职业技术学院 | 2018-02-02 | — | — | CN | disclosed |
| EP-3251679-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-12-06 | — | — | EP | disclosed |
| CN-105061373-B | A kind of synthetic method of Dapagliflozin isomer impurities | 合肥华方医药科技有限公司 | 2017-10-20 | — | — | CN | disclosed |
| EP-2896397-B1 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-20170247356-A1 | PROCESSES FOR THE PREPARATION OF EMPAGLIFLOZIN | CADILA HEALTHCARE LIMITED | 2017-08-31 | — | — | US | disclosed |
| CN-106977472-A | Benzisoelenazolone modifies nitrosourea compound synthesis and its application | 凯熙医药（天津）有限公司 | 2017-07-25 | — | — | CN | disclosed |
| US-20170101388-A1 | C-GLYCOSIDE DERIVATIVE | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-13 | — | — | US | disclosed |
| US-20170101388-A1 | C-GLYCOSIDE DERIVATIVE | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-13 | — | — | US | disclosed |
| US-20170101388-A1 | C-GLYCOSIDE DERIVATIVE | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-13 | — | — | US | disclosed |
| WO-2017042683-A1 | ISOLATED INTERMEDIATE OF DAPAGLIFLOZIN, PROCESS FOR THE PREPARATION OF ISOLATED INTERMEDIATE OF DAPAGLIFLOZIN, PROCESS FOR THE PREPARATION OF DAPAGLIFLOZIN | DR. REDDY'S LABORATORIES LIMITED (IN) | 2017-03-16 | — | — | WO | disclosed |
| EP-2803662-B1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-9573943-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20170042925-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| US-20170042925-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| US-20170042925-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| CN-104761522-B | Optically pure benzyl-4-chlorophenyl C-glycoside derivatives | 山东轩竹医药科技有限公司 | 2017-02-15 | — | — | CN | disclosed |
| US-9562029-B2 | C-glycoside derivatives | Xuanzhu Pharma Co., Ltd. (CN) | 2017-02-07 | — | — | US | disclosed |
| US-9562029-B2 | C-glycoside derivatives | Xuanzhu Pharma Co., Ltd. (CN) | 2017-02-07 | — | — | US | disclosed |
| US-9562029-B2 | C-glycoside derivatives | Xuanzhu Pharma Co., Ltd. (CN) | 2017-02-07 | — | — | US | disclosed |
| CN-106349201-A | Optically-pure benzyl-4-chlorophenyl C-glycoside derivatives | 山东轩竹医药科技有限公司 | 2017-01-25 | — | — | CN | disclosed |
| CN-106316803-A | SGLT-2 inhibitor intermediate synthesis method | 重庆博腾制药科技股份有限公司 | 2017-01-11 | — | — | CN | disclosed |
| US-9505746-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| EP-2953927-B1 | SUBSTITUTED BENZAMIDES WITH ACTIVITY TOWARDS EP4 RECEPTORS | DRACONIS PHARMA S L (ES) | 2016-11-16 | — | — | EP | disclosed |
| WO-2016178148-A1 | PROCESS FOR PREPARATION OF DAPAGLIFLOZIN | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-11-10 | — | — | WO | disclosed |
| US-20160318965-A1 | Process for the Preparation of Empagliflozin | MYLANLABORATORIES LTD. (IN) | 2016-11-03 | — | — | US | disclosed |
| EP-2556066-B1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2016-10-19 | — | — | EP | disclosed |
| EP-2895490-B1 | GLUCOPYRANOSYL DERIVATIVES AND THEIR USES IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-10-19 | — | — | EP | disclosed |
| EP-2324002-B1 | PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS | THERACOS SUB LLC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-20160280619-A1 | PROCESS FOR THE PREPARATION OF 4-BROMO-1-CHLORO-2-(4-ETHOXYBENZYL)BENZENE | RANBAXY LABORATORIES LIMITED (IN) | 2016-09-29 | — | — | US | disclosed |
| US-20160280667-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2016-09-29 | — | — | US | disclosed |
| EP-3063116-A1 | PROCESS FOR THE PREPARATION OF 4-BROMO-1-CHLORO-2-(4-ETHOXYBENZYL)BENZENE | Sun Pharmaceutical Industries Ltd (IN) | 2016-09-07 | — | — | EP | disclosed |
| EP-2725031-B1 | C-GLYCOSIDE DERIVATIVES | XUANZHU PHARMA CO LTD (CN) | 2016-08-03 | — | — | EP | disclosed |
| EP-2725031-B1 | C-GLYCOSIDE DERIVATIVES | XUANZHU PHARMA CO LTD (CN) | 2016-08-03 | — | — | EP | disclosed |
| US-20160213652-A1 | Cyclic Ether Pyrazol-4-YL-Heterocyclyl-Carboxamide Compounds And Methods Of Use | GENENTECH, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| US-9394329-B2 | Glucopyranosyl derivatives and their uses in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-07-19 | — | — | US | disclosed |
| US-9394329-B2 | Glucopyranosyl derivatives and their uses in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-07-19 | — | — | US | disclosed |
| US-20160194264-A1 | OPTICALLY PURE BENZYL-4-CHLOROPHENYL-C-GLUCOSIDE DERIVATIVE | Xuanzhu Pharma Co., Ltd. (CN) | 2016-07-07 | — | — | US | disclosed |
| US-20160194264-A1 | OPTICALLY PURE BENZYL-4-CHLOROPHENYL-C-GLUCOSIDE DERIVATIVE | Xuanzhu Pharma Co., Ltd. (CN) | 2016-07-07 | — | — | US | disclosed |
| US-20160194264-A1 | OPTICALLY PURE BENZYL-4-CHLOROPHENYL-C-GLUCOSIDE DERIVATIVE | Xuanzhu Pharma Co., Ltd. (CN) | 2016-07-07 | — | — | US | disclosed |
| US-9382236-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2016-07-05 | — | — | US | disclosed |
| EP-2703396-B1 | INHIBITOR OF SODIUM-DEPENDENT GLUCOSE TRANSPORT PROTEIN AND PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING PRELUDE PHARM SCI & TECH CO LTD (CN) | 2016-06-22 | — | — | EP | disclosed |
| EP-2891654-B1 | Optically pure benzyl-4-chlorophenyl-C-glucoside derivatives as SGLT inhibitors (diabetes mellitus) | XUANZHU PHARMA CO LTD (CN) | 2016-06-22 | — | — | EP | disclosed |
| EP-2891654-B1 | Optically pure benzyl-4-chlorophenyl-C-glucoside derivatives as SGLT inhibitors (diabetes mellitus) | XUANZHU PHARMA CO LTD (CN) | 2016-06-22 | — | — | EP | disclosed |
| CN-105693669-A | Antidiabetic compound and preparation method and application thereof | 南昌大学 | 2016-06-22 | — | — | CN | disclosed |
| US-9328106-B2 | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| EP-2604612-B1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION RPOCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2016-04-20 | — | — | EP | disclosed |
| EP-2604612-B1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION RPOCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2016-04-20 | — | — | EP | disclosed |
| US-9315438-B2 | Optically pure benzyl-4-chlorophenyl-C-glucoside derivative | XUANZHU PHARMA CO., LTD (CN) | 2016-04-19 | — | — | US | disclosed |
| US-9315438-B2 | Optically pure benzyl-4-chlorophenyl-C-glucoside derivative | XUANZHU PHARMA CO., LTD (CN) | 2016-04-19 | — | — | US | disclosed |
| US-9315438-B2 | Optically pure benzyl-4-chlorophenyl-C-glucoside derivative | XUANZHU PHARMA CO., LTD (CN) | 2016-04-19 | — | — | US | disclosed |
| CN-102625807-B | 4-Substituted pyridin-3-yl-carboxamide compounds and methods of use | HOFFMAN-LA ROCHE LTD. (CH) | 2016-03-09 | — | — | CN | disclosed |
| EP-2491029-B1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2016-02-10 | — | — | EP | disclosed |
| US-20150376129-A1 | SUBSTITUTED BENZAMIDES WITH ACTIVITY TOWARDS EP4 RECEPTORS | DRACONIS PHARMA, S.L. (ES) | 2015-12-31 | — | — | US | disclosed |
| EP-2953927-A1 | SUBSTITUTED BENZAMIDES WITH ACTIVITY TOWARDS EP4 RECEPTORS | Draconis Pharma, S.L. (ES) | 2015-12-16 | — | — | EP | disclosed |
| US-20150329501-A1 | SUBSTITUTED [1,2,4]TRIAZOLE COMPOUNDS AND THEIR USE AS FUNGICIDES | BASF SE (DE) | 2015-11-19 | — | — | US | disclosed |
| CN-105061373-A | Synthesis method of dapagliflozin isomer impurity | HEFEI HUAFANG PHARMACEUTICAL SCIENCES & TECHNOLOGY CO LTD | 2015-11-18 | — | — | CN | disclosed |
| EP-2475659-B1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2015-10-28 | — | — | EP | disclosed |
| EP-2935237-A1 | SUBSTITUTED [1,2,4]TRIAZOLE COMPOUNDS AND THEIR USE AS FUNGICIDES | BASF SE (DE) | 2015-10-28 | — | — | EP | disclosed |
| US-20150266916-A1 | GLUCOPYRANOSYL DERIVATIVES AND THEIR USES IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-09-24 | — | — | US | disclosed |
| US-20150266916-A1 | GLUCOPYRANOSYL DERIVATIVES AND THEIR USES IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-09-24 | — | — | US | disclosed |
| CN-104086379-B | The synthetic method of the clean intermediate of Da Gelie | ANHUI LIANCHUANG BIOLOGICAL MEDICINE CO., LTD. (CN) | 2015-08-12 | — | — | CN | disclosed |
| EP-2900657-A1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2015-08-05 | — | — | EP | disclosed |
| CN-102757415-B | A kind of sodium dependent glucose transporter inhibitors and its production and use | BEIJING PRELUDE PHARM TECHNOLOGY CO., LTD. (CN) | 2015-07-29 | — | — | CN | disclosed |
| EP-2896397-A1 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-07-22 | — | — | EP | disclosed |
| US-20150191502-A1 | OPTICALLY PURE BENZYL-4-CHLOROPHENYL-C-GLUCOSIDE DERIVATIVE | Xuanzhu Pharma Co., Ltd. (CN) | 2015-07-09 | — | — | US | disclosed |
| US-20150191502-A1 | OPTICALLY PURE BENZYL-4-CHLOROPHENYL-C-GLUCOSIDE DERIVATIVE | Xuanzhu Pharma Co., Ltd. (CN) | 2015-07-09 | — | — | US | disclosed |
| US-20150191502-A1 | OPTICALLY PURE BENZYL-4-CHLOROPHENYL-C-GLUCOSIDE DERIVATIVE | Xuanzhu Pharma Co., Ltd. (CN) | 2015-07-09 | — | — | US | disclosed |
| EP-2891654-A1 | Optically pure benzyl-4-chlorophenyl-C-glucoside derivatives as SGLT inhibitors (diabetes mellitus) | Xuanzhu Pharma Co., Ltd. (CN) | 2015-07-08 | — | — | EP | disclosed |
| EP-2891654-A1 | Optically pure benzyl-4-chlorophenyl-C-glucoside derivatives as SGLT inhibitors (diabetes mellitus) | Xuanzhu Pharma Co., Ltd. (CN) | 2015-07-08 | — | — | EP | disclosed |
| US-9061060-B2 | Deuterated benzylbenzene derivatives and methods of use | THERACOS INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9061060-B2 | Deuterated benzylbenzene derivatives and methods of use | THERACOS INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150141354-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-21 | — | — | US | disclosed |
| US-20150141354-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-21 | — | — | US | disclosed |
| US-20150141354-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-21 | — | — | US | disclosed |
| CN-104640858-A | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | HOFFMANN LA ROCHE | 2015-05-20 | — | — | CN | disclosed |
| WO-2015063726-A1 | PROCESS FOR THE PREPARATION OF 4-BROMO-1-CHLORO-2-(4-ETHOXYBENZYL)BENZENE | RANBAXY LABORATORIES LIMITED (IN) | 2015-05-07 | — | — | WO | disclosed |
| US-9006403-B2 | Processes for the preparation of SGLT2 inhibitors | THERACOS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006403-B2 | Processes for the preparation of SGLT2 inhibitors | THERACOS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| WO-2015043511-A1 | GLUCOPYRANOSYL DERIVATIVES AND THEIR USES IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-04-02 | — | — | WO | disclosed |
| US-8957033-B2 | Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof | BEIJING PRELUDE PHARM. SCI. & TECH. CO., LTD. (CN) | 2015-02-17 | — | — | US | disclosed |
| US-8957033-B2 | Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof | BEIJING PRELUDE PHARM. SCI. & TECH. CO., LTD. (CN) | 2015-02-17 | — | — | US | disclosed |
| US-8957033-B2 | Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof | BEIJING PRELUDE PHARM. SCI. & TECH. CO., LTD. (CN) | 2015-02-17 | — | — | US | disclosed |
| CN-102656165-B | Glycoside derivatives and uses thereof | NOVARTIS AG | 2015-02-11 | — | — | CN | disclosed |
| CN-104341444-A | Empagliflozin silicon-containing aglycone as well as preparation method and application thereof | UNIV GUANGXI CHINESE MEDICINE | 2015-02-11 | — | — | CN | disclosed |
| CN-104230866-A | C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO | 2014-12-24 | — | — | CN | disclosed |
| EP-2514756-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-20140357858-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2014-12-04 | — | — | US | disclosed |
| EP-2803662-A1 | P2X4 RECEPTOR ANTAGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2014-11-19 | — | — | EP | disclosed |
| CN-104109179-A | C-aryl glucoside derivatives, preparation method and application thereof | HANGZHOU HUADONG MEDICINE GROUP BIOLOGY ENG RES CO LTD | 2014-10-22 | — | — | CN | disclosed |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140274921-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140274921-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140274921-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8828951-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-8828951-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-8828951-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-20140243517-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | ASTRAZENECA AB (SE) | 2014-08-28 | — | — | US | disclosed |
| US-20140243517-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | ASTRAZENECA AB (SE) | 2014-08-28 | — | — | US | disclosed |
| US-20140243517-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | ASTRAZENECA AB (SE) | 2014-08-28 | — | — | US | disclosed |
| CN-102627676-B | C-aryl glucoside sglt2 inhibitors and method | ASTRAZENECA CORP | 2014-08-20 | — | — | CN | disclosed |
| WO-2014122267-A1 | SUBSTITUTED BENZAMIDES WITH ACTIVITY TOWARDS EP4 RECEPTORS | DRACONIS PHARMA, S.L. (ES) | 2014-08-14 | — | — | WO | disclosed |
| EP-2765128-A1 | Substituted benzamides with activity towards EP4 receptors | Almirall, S.A. (ES) | 2014-08-13 | — | — | EP | disclosed |
| US-8802637-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| EP-2760857-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8785403-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-22 | — | — | US | disclosed |
| CN-103896752-A | Preparation method of 4-chloro-3-(4-ethoxybenzyl)benzaldehyde | SHANGHAI SUN SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO LTD | 2014-07-02 | — | — | CN | disclosed |
| WO-2014095672-A1 | SUBSTITUTED [1,2,4]TRIAZOLE COMPOUNDS AND THEIR USE AS FUNGICIDES | BASF SE (DE) | 2014-06-26 | — | — | WO | disclosed |
| US-20140128376-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128331-A1 | C-GLYCOSIDE DERIVATIVES | Xuanzhu Pharma Co., Ltd. (CN) | 2014-05-08 | — | — | US | disclosed |
| US-20140128331-A1 | C-GLYCOSIDE DERIVATIVES | Xuanzhu Pharma Co., Ltd. (CN) | 2014-05-08 | — | — | US | disclosed |
| US-20140128331-A1 | C-GLYCOSIDE DERIVATIVES | Xuanzhu Pharma Co., Ltd. (CN) | 2014-05-08 | — | — | US | disclosed |
| EP-2725031-A1 | C-GLYCOSIDE DERIVATIVES | Xuanzhu Pharma Co., Ltd. (CN) | 2014-04-30 | — | — | EP | disclosed |
| EP-2725031-A1 | C-GLYCOSIDE DERIVATIVES | Xuanzhu Pharma Co., Ltd. (CN) | 2014-04-30 | — | — | EP | disclosed |
| US-20140088117-A1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140080801-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8673948-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2014-03-18 | — | — | US | disclosed |
| US-8669361-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-11 | — | — | US | disclosed |
| EP-2703396-A1 | INHIBITOR OF SODIUM-DEPENDENT GLUCOSE TRANSPORT PROTEIN AND PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Prelude Pharm. Sci.& Tech. Co., Ltd. (CN) | 2014-03-05 | — | — | EP | disclosed |
| EP-2703396-A1 | INHIBITOR OF SODIUM-DEPENDENT GLUCOSE TRANSPORT PROTEIN AND PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Prelude Pharm. Sci.& Tech. Co., Ltd. (CN) | 2014-03-05 | — | — | EP | disclosed |
| US-20140051648-A1 | Inhibitor of Sodium-Dependent Glucose Transport Protein and Preparation Method Therefor and Use Thereof | BEIJING PRELUDE PHARM. SCI. & TECH. CO., LTD. (CN) | 2014-02-20 | — | — | US | disclosed |
| US-20140051648-A1 | Inhibitor of Sodium-Dependent Glucose Transport Protein and Preparation Method Therefor and Use Thereof | BEIJING PRELUDE PHARM. SCI. & TECH. CO., LTD. (CN) | 2014-02-20 | — | — | US | disclosed |
| US-20140051648-A1 | Inhibitor of Sodium-Dependent Glucose Transport Protein and Preparation Method Therefor and Use Thereof | BEIJING PRELUDE PHARM. SCI. & TECH. CO., LTD. (CN) | 2014-02-20 | — | — | US | disclosed |
| CN-103570510-A | One-pot synthesis method for 5-bromo-2-chloro-4'-ethoxy diphenylmethane | CHINATECH PEPTIDE CO LTD | 2014-02-12 | — | — | CN | disclosed |
| CN-103570510-A | One-pot synthesis method for 5-bromo-2-chloro-4'-ethoxy diphenylmethane | CHINATECH PEPTIDE CO LTD | 2014-02-12 | — | — | CN | disclosed |
| US-20140031300-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2079466-B1 | SUBSTITUTED INDOLE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8614206-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-24 | — | — | US | disclosed |
| US-8609622-B2 | C-aryl glucoside derivatives, preparation process and pharmaceutical use thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2013-12-17 | — | — | US | disclosed |
| US-8575321-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130203732-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2604612-A1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION RPOCESS AND PHARMACEUTICAL USE THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2013-06-19 | — | — | EP | disclosed |
| US-8466114-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2013-06-18 | — | — | US | disclosed |
| US-8466114-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2013-06-18 | — | — | US | disclosed |
| US-8466114-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2013-06-18 | — | — | US | disclosed |
| US-20130130997-A1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2013-05-23 | — | — | US | disclosed |
| US-20130130997-A1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2013-05-23 | — | — | US | disclosed |
| US-20130130997-A1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2013-05-23 | — | — | US | disclosed |
| US-8436001-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-07 | — | — | US | disclosed |
| US-8435976-B2 | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE (CH) | 2013-05-07 | — | — | US | disclosed |
| WO-2013045461-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-04 | — | — | WO | disclosed |
| US-20130079321-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130046088-A1 | Processes for the Preparation of SGLT2 Inhibitors | THERACOS, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130046088-A1 | Processes for the Preparation of SGLT2 Inhibitors | THERACOS, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| EP-2556066-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2013-02-13 | — | — | EP | disclosed |
| US-20130017993-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | disclosed |
| US-20130017993-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | disclosed |
| US-20130017993-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | disclosed |
| EP-1651658-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-102875503-A | C-glucoside derivative | KBP BIOSCIENCES CO LTD | 2013-01-16 | — | — | CN | disclosed |
| CN-102863417-A | C-indican derivative | KBP BIOSCIENCES CO LTD | 2013-01-09 | — | — | CN | disclosed |
| US-20120329732-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| CN-102757415-A | Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof | BEIJING PRELUDE PHARM SCI & TECH CO LTD | 2012-10-31 | — | — | CN | disclosed |
| EP-2514756-A1 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-10-24 | — | — | EP | disclosed |
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-10-11 | — | — | US | disclosed |
| US-8283454-B2 | Processes for the preparation of SGLT2 inhibitors | THERACOS, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283454-B2 | Processes for the preparation of SGLT2 inhibitors | THERACOS, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| CN-102656165-A | Glycoside derivatives and uses thereof | NOVARTIS AG | 2012-09-05 | — | — | CN | disclosed |
| EP-2491029-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| CN-102627676-A | C-aryl glucoside sglt2 inhibitors and method | BRISTOL MYERS SQUIBB CO | 2012-08-08 | — | — | CN | disclosed |
| EP-2475659-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| US-8222219-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2012-07-12 | — | — | US | disclosed |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2012-07-12 | — | — | US | disclosed |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2012-07-12 | — | — | US | disclosed |
| US-8202984-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-19 | — | — | US | disclosed |
| US-8163704-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-8163704-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-8163704-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| CN-101628905-B | C-aryl glucoside sglt2 inhibitors and method | BRISTOL MYERS SQUIBB CO | 2012-03-21 | — | — | CN | disclosed |
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| US-8129434-B2 | Benzylphenyl cyclohexane derivatives and methods of use | THERACOS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| WO-2012025857-A1 | CYCLOALKYL METHOXYBENZYL PHENYL PYRAN DERIVATIVES AS SODIUM DEPENDENT GLUCOSE CO TRANSPORTER (SGLT2) INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012019496-A1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION RPOCESS AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-02-16 | — | — | WO | disclosed |
| US-8106021-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110301203-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-12-08 | — | — | US | disclosed |
| CN-102234260-A | C-aryl glucoside derivatives containing difluoromethylene group | SHANGHAI SUN SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO LTD | 2011-11-09 | — | — | CN | disclosed |
| EP-1399416-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-11-02 | — | — | EP | disclosed |
| WO-2011124580-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-13 | — | — | WO | disclosed |
| US-20110251176-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-10-13 | — | — | US | disclosed |
| US-8026262-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-20110207661-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110201795-A1 | Methods of Producing C-Aryl Glucoside SGLT2 Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201795-A1 | Methods of Producing C-Aryl Glucoside SGLT2 Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201795-A1 | Methods of Producing C-Aryl Glucoside SGLT2 Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | US | disclosed |
| CN-101065391-B | C-aryl glucoside sglt2 inhibitors and method | BRISTOL MYERS SQUIBB CO | 2011-07-27 | — | — | CN | disclosed |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-7943788-B2 | Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
| WO-2011048112-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011048112-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-04-28 | — | — | WO | disclosed |
| US-7932379-B2 | Methods of producing C-aryl glucoside SGLT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932379-B2 | Methods of producing C-aryl glucoside SGLT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932379-B2 | Methods of producing C-aryl glucoside SGLT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-26 | — | — | US | disclosed |
| WO-2011029802-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20110059961-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-03-10 | — | — | US | disclosed |
| US-20110059910-A1 | Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds and the use thereof | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | US | disclosed |
| US-20110059910-A1 | Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds and the use thereof | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | US | disclosed |
| CN-101938902-A | Benzylphenylcyclohexane derivatives and methods of use | THERACOS INC | 2011-01-05 | — | — | CN | disclosed |
| US-7838499-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| EP-2230907-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | Theracos, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100222599-A1 | PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS | THERACOSBIO, LLC | 2010-09-02 | — | — | US | disclosed |
| US-20100222599-A1 | PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS | THERACOSBIO, LLC | 2010-09-02 | — | — | US | disclosed |
| US-20100167988-A1 | ETHOXYPHENYLMETHYL INHIBITORS OF SGLT2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100167988-A1 | ETHOXYPHENYLMETHYL INHIBITORS OF SGLT2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100167988-A1 | ETHOXYPHENYLMETHYL INHIBITORS OF SGLT2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| CN-101754972-A | Crystal structure of SGLT2 inhibitor and preparation method thereof | BRISTOL MYERS SQUIBB CO | 2010-06-23 | — | — | CN | disclosed |
| EP-2187742-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | Theracos, Inc. (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2010048358-A2 | ETHOXYPHENYLMETHYL INHIBITORS OF SGLT2 | AUSPEX PHARMACEUTICAL, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010048358-A2 | ETHOXYPHENYLMETHYL INHIBITORS OF SGLT2 | AUSPEX PHARMACEUTICAL, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20100063141-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063141-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| WO-2010022313-A2 | PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS | THERACOS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| EP-2147008-A2 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | Bristol-Myers Squibb Company (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2010009243-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| CN-101628905-A | C-aryl glucoside SGLT2 inhibitors and method | BRISTOL MYERS SQUIBB CO | 2010-01-20 | — | — | CN | disclosed |
| US-20090264482-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-22 | — | — | US | disclosed |
| US-7589193-B2 | C-aryl glucoside SGLT2 inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589193-B2 | C-aryl glucoside SGLT2 inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589193-B2 | C-aryl glucoside SGLT2 inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| CN-100534997-C | C-aryl glucoside SGLT2 inhibitors and methods | BRISTOL MYERS SQUIBB CO (US) | 2009-09-02 | — | — | CN | disclosed |
| WO-2009100936-A2 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, PHARMACEUTICALS COMPRISING SAID COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-20 | — | — | WO | disclosed |
| US-7572820-B2 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-11 | — | — | US | disclosed |
| EP-2079466-A2 | SUBSTITUTED INDOLE COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090156516-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | SEED, BRIAN | 2009-06-18 | — | — | US | disclosed |
| WO-2009076550-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090118201-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOSBIO, LLC | 2009-05-07 | — | — | US | disclosed |
| EP-2046346-A1 | NOVEL SGLT INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-04-15 | — | — | EP | disclosed |
| EP-1791852-B8 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD FOR THEIR PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2009026537-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| EP-1791852-B1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD FOR THEIR PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2008-12-31 | — | — | EP | disclosed |
| WO-2008144346-A2 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR THEIR PREPARATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080287529-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-20 | — | — | US | disclosed |
| CN-101260130-A | Methods of producing C-aryl glucoside SGLT2 inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2008-09-10 | — | — | CN | disclosed |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| CN-100391963-C | Process for preparing C-aryl glucoside SGLT2 inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2008-06-04 | — | — | CN | disclosed |
| US-7375213-B2 | inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2), and more particularly to a process of producing such compounds, for example dapagliflozin | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375213-B2 | inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2), and more particularly to a process of producing such compounds, for example dapagliflozin | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375213-B2 | inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2), and more particularly to a process of producing such compounds, for example dapagliflozin | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-20 | — | — | US | disclosed |
| WO-2008042571-A2 | SUBSTITUTED INDOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-10 | — | — | WO | disclosed |
| EP-1581543-A4 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-03-19 | — | — | EP | disclosed |
| US-20080027014-A1 | Novel SGLT inhibitors | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| WO-2008013321-A1 | NOVEL SGLT INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-01-31 | — | — | WO | disclosed |
| CN-101092409-A | C-aryl glucoside sglt2 inhibitors and method | BRISTOL MYERS SQUIBB CO (US) | 2007-12-26 | — | — | CN | disclosed |
| CN-101065391-A | C-aryl glucoside sglt2 inhibitors and method | BRISTOL MYERS SQUIBB CO (US) | 2007-10-31 | — | — | CN | disclosed |
| US-20070238866-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
| US-20070238866-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
| US-20070238866-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
| US-20070135497-A1 | Biphenyl derivative or its salt, and pesticide containing it as an active ingredient | ISHIHARA SANGYO KAISHA LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1791852-A2 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD FOR THEIR PRODUCTION | Brystol-Myers Squibb Company (US) | 2007-06-06 | — | — | EP | disclosed |
| EP-1506211-B1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2007-02-07 | — | — | EP | disclosed |
| EP-1681924-A1 | BIPHENYL DERIVATIVE OR ITS SALT, AND PESTICIDE CONTAINING IT AS AN ACTIVE INGREDIENT | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2006-07-26 | — | — | EP | disclosed |
| EP-1651658-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2006-05-03 | — | — | EP | disclosed |
| CN-1756759-A | Process for preparing C-aryl glucoside SGLT2 inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2006-04-05 | — | — | CN | disclosed |
| WO-2006034489-A2 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD FOR THEIR PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063722-A1 | C-aryl glucoside SGLT2 inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-23 | — | — | US | disclosed |
| EP-1399416-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050233988-A1 | Novel compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-20 | — | — | US | disclosed |
| EP-1581543-A2 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-10-05 | — | — | EP | disclosed |
| US-6936590-B2 | C-aryl glucoside SGLT2 inhibitors and method | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| EP-1506211-A4 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2005-08-17 | — | — | EP | disclosed |
| CN-1653075-A | C-aryl glucoside SGLT2 inhibitors and methods | BRISTOL MYERS SQUIBB CO (US) | 2005-08-10 | — | — | CN | disclosed |
| WO-2005044007-A1 | BIPHENYL DERIVATIVE OR ITS SALT, AND PESTICIDE CONTAINING IT AS AN ACTIVE INGREDIENT | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2005-05-19 | — | — | WO | disclosed |
| EP-1224195-B1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-05-18 | — | — | EP | disclosed |
| EP-1506211-A1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2005012326-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-10 | — | — | WO | disclosed |
| US-6852882-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040157916-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2004-08-12 | — | — | US | disclosed |
| WO-2004063209-A2 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040138439-A1 | inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2), and more particularly to a process of producing such compounds, for example 1-C-(substituted diphenylmethane-3-yl)- beta -D-glucopyranose | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
| EP-1399416-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003099836-A1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030114390-A1 | C-aryl glucoside SGLT2 inhibitors and method | ASTRAZENECA AB (SE) | 2003-06-19 | — | — | US | disclosed |
| US-6515117-B2 | Sodium dependent glucose transporters found in the intestine and kidney (SGLT2); treating diabetes; compound dapagliflozin | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-04 | — | — | US | disclosed |
| WO-2002098901-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
| US-20020137903-A1 | C-aryl glucoside SGLT2 inhibitors and method | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
| EP-1224195-A1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6414126-B1 | ANTIDIABETIC, ANTIOBESITY, ANTILIPEMIC, ANTIATHEROSCLEROTIC, ANTICOAGULANT, AND HYPOTENSIVE AGENTS; MARKUSH ENCOMPASSING DAPAGLIFOZIN AND DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-02 | — | — | US | disclosed |
| WO-2001027128-A1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
| EP-0043936-B1 | METHOD FOR THE PREPARATION OF BENZO-1,2-DITHIOL-3-THIONES | BASF Aktiengesellschaft (DE) | 1984-09-05 | — | — | EP | disclosed |
| EP-0043936-A1 | Method for the preparation of benzo-1,2-dithiol-3-thiones | BASF Aktiengesellschaft (DE) | 1982-01-20 | — | — | EP | disclosed |
| EP-0043936-A1 | Method for the preparation of benzo-1,2-dithiol-3-thiones | BASF Aktiengesellschaft (DE) | 1982-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287529-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | SLC5A2, SLC5A1, SLC2A1 | ALDH1A1 1812/4885HPGD 288/4885CYP1A2 545/4885 |
| US-20150376129-A1 | SUBSTITUTED BENZAMIDES WITH ACTIVITY TOWARDS EP4 RECEPTORS | PTGER4, PTGER1, PTGER2 | ALDH1A1 493/4885HPGD 693/4885CYP1A2 438/4885 |
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | ALDH1A1 873/4885HPGD 612/4885CYP1A2 129/4885 |
| US-20190202814-A1 | PROCESSES FOR PREPARATION OF EMPAGLIFLOZIN | SLC5A2, SLC5A1, SLC2A4 | ALDH1A1 3250/4885HPGD 1849/4885CYP1A2 253/4885 |
| US-20140128376-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | ALDH1A1 1703/4885HPGD 1285/4885CYP1A2 2068/4885 |
| US-20170042925-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | ALDH1A1 482/4885HPGD 423/4885CYP1A2 703/4885 |
| US-20030114390-A1 | C-aryl glucoside SGLT2 inhibitors and method | SLC5A2, SLC5A1, UGGT1 | ALDH1A1 641/4885HPGD 1204/4885CYP1A2 209/4885 |
| US-10556877-B2 | Process for preparation of dapagliflozin | SLC5A2, SLC5A1, DPP4 | ALDH1A1 1843/4885HPGD 599/4885CYP1A2 240/4885 |
| US-20050233988-A1 | Novel compounds | CYP1B1, CYP4B1, CYP2B6 | ALDH1A1 831/4885HPGD 391/4885CYP1A2 21/4885 |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | ALDH1A1 482/4885HPGD 423/4885CYP1A2 703/4885 |
| US-20090264482-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | ALDH1A1 671/4885HPGD 415/4885CYP1A2 141/4885 |
| US-20110251176-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | ALDH1A1 1703/4885HPGD 1285/4885CYP1A2 2068/4885 |
| US-20150191502-A1 | OPTICALLY PURE BENZYL-4-CHLOROPHENYL-C-GLUCOSIDE DERIVATIVE | SLC5A2, SLC5A1, GCG | ALDH1A1 2423/4885HPGD 1602/4885CYP1A2 482/4885 |
| US-10981888-B2 | Preparation method for tricyclic compounds | CYP4B1, CYP3A4, CYP1A1 | ALDH1A1 310/4885HPGD 644/4885CYP1A2 5/4885 |
| US-20190315707-A1 | PREPARATION METHOD FOR TRICYCLIC COMPOUNDS | CYP4B1, CYP3A4, CYP1A1 | ALDH1A1 310/4885HPGD 644/4885CYP1A2 5/4885 |
| US-20220380322-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | ALDH1A1 3019/4885HPGD 1251/4885CYP1A2 1236/4885 |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | ALDH1A1 873/4885HPGD 612/4885CYP1A2 129/4885 |
| US-20160318965-A1 | Process for the Preparation of Empagliflozin | SLC5A1, SLC5A2, SLC2A4 | ALDH1A1 437/4885HPGD 208/4885CYP1A2 95/4885 |
| US-20240245633-A1 | ROR Gamma Agonists as Enhancers of Protective Immunity | RORC, RORB, RORA | ALDH1A1 1575/4885HPGD 2428/4885CYP1A2 2234/4885 |
| US-20140128331-A1 | C-GLYCOSIDE DERIVATIVES | RDX, C3AR1, C1R | ALDH1A1 1222/4885HPGD 2462/4885CYP1A2 160/4885 |
| US-20220372010-A1 | PROCESSES FOR PREPARATION OF DAPAGLIFLOZIN OR ITS SOLVATES OR CO-CRYSTALS THEREOF | SLC5A1, SLC5A2, DPP4 | ALDH1A1 1691/4885HPGD 953/4885CYP1A2 475/4885 |
| US-20110207661-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A4 | ALDH1A1 722/4885HPGD 1142/4885CYP1A2 585/4885 |
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | ALDH1A1 3045/4885HPGD 974/4885CYP1A2 1195/4885 |
| US-12116351-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | ALDH1A1 3019/4885HPGD 1251/4885CYP1A2 1236/4885 |
| US-20070238866-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | SLC5A2, SLC5A1, GCG | ALDH1A1 1400/4885HPGD 970/4885CYP1A2 447/4885 |
| US-20160194264-A1 | OPTICALLY PURE BENZYL-4-CHLOROPHENYL-C-GLUCOSIDE DERIVATIVE | SLC5A2, SLC5A1, GCG | ALDH1A1 2423/4885HPGD 1602/4885CYP1A2 482/4885 |
| US-20110201795-A1 | Methods of Producing C-Aryl Glucoside SGLT2 Inhibitors | SLC5A2, SLC5A1, GCG | ALDH1A1 1400/4885HPGD 970/4885CYP1A2 447/4885 |
| US-20080027014-A1 | Novel SGLT inhibitors | SLC5A1, SLC5A2, SLC10A1 | ALDH1A1 670/4885HPGD 2123/4885CYP1A2 2114/4885 |
| US-20090118201-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A4 | ALDH1A1 722/4885HPGD 1142/4885CYP1A2 585/4885 |
| US-20110301203-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | ALDH1A1 671/4885HPGD 415/4885CYP1A2 141/4885 |
| US-20170247356-A1 | PROCESSES FOR THE PREPARATION OF EMPAGLIFLOZIN | SLC5A2, SLC5A1, SLC2A4 | ALDH1A1 3461/4885HPGD 1851/4885CYP1A2 292/4885 |
| US-20210388016-A1 | GLUCOPYRANOSE DERIVATIVES USEFUL AS SGLT2 INHIBITORS | SLC5A2, SLC5A1, UGGT1 | ALDH1A1 1242/4885HPGD 1143/4885CYP1A2 497/4885 |
| US-20160280667-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | ALDH1A1 3013/4885HPGD 1247/4885CYP1A2 1249/4885 |
| US-20140357858-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | ALDH1A1 3019/4885HPGD 1251/4885CYP1A2 1236/4885 |
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | ALDH1A1 873/4885HPGD 612/4885CYP1A2 129/4885 |
| US-20090156516-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A8 | ALDH1A1 1619/4885HPGD 700/4885CYP1A2 608/4885 |
| US-20100222599-A1 | PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS | SLC5A2, SLC5A1, SLC2A4 | ALDH1A1 2514/4885HPGD 3408/4885CYP1A2 1358/4885 |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | ALDH1A1 3019/4885HPGD 1251/4885CYP1A2 1236/4885 |
| US-11434207-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | ALDH1A1 3019/4885HPGD 1251/4885CYP1A2 1236/4885 |
| US-20150141354-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | ALDH1A1 482/4885HPGD 423/4885CYP1A2 703/4885 |
| US-20120329732-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A4 | ALDH1A1 722/4885HPGD 1142/4885CYP1A2 585/4885 |
| US-20130017993-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | ALDH1A1 482/4885HPGD 423/4885CYP1A2 703/4885 |
| US-20180282363-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | ALDH1A1 873/4885HPGD 612/4885CYP1A2 129/4885 |
| US-20160213652-A1 | Cyclic Ether Pyrazol-4-YL-Heterocyclyl-Carboxamide Compounds And Methods Of Use | PIM1, PIM2, PIM3 | ALDH1A1 3026/4885HPGD 2075/4885CYP1A2 1557/4885 |
| US-20060063722-A1 | C-aryl glucoside SGLT2 inhibitors and method | SLC5A2, SLC5A1, GCG | ALDH1A1 700/4885HPGD 1105/4885CYP1A2 195/4885 |
| US-20150266916-A1 | GLUCOPYRANOSYL DERIVATIVES AND THEIR USES IN MEDICINE | SLC5A2, SLC5A1, UGGT1 | ALDH1A1 561/4885HPGD 526/4885CYP1A2 768/4885 |
| US-20130046088-A1 | Processes for the Preparation of SGLT2 Inhibitors | SLC5A2, SLC5A1, SLC2A4 | ALDH1A1 2514/4885HPGD 3408/4885CYP1A2 1358/4885 |
| US-20140031300-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A4 | ALDH1A1 722/4885HPGD 1142/4885CYP1A2 585/4885 |
| US-20180127391-A1 | PROCESS FOR PREPARATION OF DAPAGLIFLOZIN | SLC5A2, SLC5A1, DPP4 | ALDH1A1 1843/4885HPGD 599/4885CYP1A2 240/4885 |
| US-10633349-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | ALDH1A1 3019/4885HPGD 1251/4885CYP1A2 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.